The status quo of cannabis medicine for most patients still involves the black market with its myriad risks and inherent lack of quality control. An additional requirement is a supply chain that ensures security that it is being distributed to its intended target patients. It must also possess a practical and suitable delivery system that minimizes patient risk, including intoxication, other aspects of drug abuse liability (DAL) or serious adverse events, such as pulmonary sequelae. It follows the same time-honored process that any pharmaceutical must attain to receive regulatory approval: proof of biochemical uniformity and stability along with safety and efficacy as proven by randomized clinical trials (RCT).Ī prescription cannabis product must be standardized, consistent and display a quality equal to any New Chemical Entity that has passed muster as a pharmaceutical ( Russo, 2006a Russo et al., 2015). Is there a pathway that will lead to the return of cannabis to mainstream medicine? The answer is clear, inasmuch as it has already commenced. With ongoing developments in legalization of cannabis in medical and recreational settings, numerous scientific, safety, and public health issues remain. New and disturbing data on pesticide residues in legal cannabis products in Washington State are presented with the observation of an 84.6% contamination rate including potentially neurotoxic and carcinogenic agents. Finally, the issue of pesticide usage on cannabis crops is addressed.
#Advent 7113 drivers plus
This overview covers a wide range of cannabis topics, initially examining issues in dispensaries and self-administration, plus regulatory requirements for production of cannabis-based medicines, particularly the Food and Drug Administration “ Botanical Guidance.” The remainder pertains to various cannabis controversies that certainly require closer examination if the scientific, consumer, and governmental stakeholders are ever to reach consensus on safety issues, specifically: whether botanical cannabis displays herbal synergy of its components, pharmacokinetics of cannabis and dose titration, whether cannabis medicines produce cyclo-oxygenase inhibition, cannabis-drug interactions, and cytochrome P450 issues, whether cannabis randomized clinical trials are properly blinded, combatting the placebo effect in those trials via new approaches, the drug abuse liability (DAL) of cannabis-based medicines and their regulatory scheduling, their effects on cognitive function and psychiatric sequelae, immunological effects, cannabis and driving safety, youth usage, issues related to cannabis smoking and vaporization, cannabis concentrates and vape-pens, and laboratory analysis for contamination with bacteria and heavy metals.
Smoking and Vaporizers (Adapted and Updated from Russo And Hohmann, 2013).Cognitive Issues and Neuropsychiatric Sequelae.Cannabis, Drug Abuse Liability, and DEA Scheduling.Blinding, Placebo, and Design Issues in Cannabis Randomized Clinical Trials.
Anti-Inflammatory Drugs and Cyclo-Oxygenase (COX) Inhibition.Pharmacokinetics and Cannabinoid Dose Titration.Can a Botanical Agent Become a Prescription Medicine?.Controversies in Cannabis Dispensaries, Coffee Shops, and Self-Administration.The editor and reviewer's affiliations are the latest provided on their Loop research profiles and may not reflect their situation at the time of review.
0 kommentar(er)
